Docetaxel（Trihydrate）CAS NO:148408-66-6

Product Description:

Product Name: Docetaxel(Trihydrate)CAS NO:148408-66-6

Synonyms:

1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate} trihydrate;

Incorrect CAS No. 148408-66-5;

DOCETAXEL HYDRATE;

DOCETAXEL TRIHYDRATE;

TC-070787, FT-0083651;

Unii-15H5577cqd;

Chemical & Physical Properties:

Appearance : white Powder

Assay : ≥99.0%, EP7.0

Density:1.37 g/cm3

Boiling Point:1016.9℃ at 760 mmHg

Melting Point:186-192℃

Flash Point:568.8℃

Applications:

Docetaxel Trihydrate is a semi-synthetic taxane analogue, acts as a microtubule stabilizer.

Docetaxel trihydrate is the trihydrate form of docetaxel. It is used for the treatment of breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer. It has a role as an antineoplastic agent. It is a hydrate and a secondary alpha-hydroxy ketone. It contains a member of docetaxel anhydrous.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.